1. Home
  2. NXTS vs ARTL Comparison

NXTS vs ARTL Comparison

Compare NXTS & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NXTS

Nexentis Technologies Inc. Common Stock

N/A

Current Price

$4.63

Market Cap

4.3M

Sector

Industrials

ML Signal

N/A

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$2.56

Market Cap

4.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NXTS
ARTL
Founded
2009
2011
Country
Israel
United States
Employees
9
7
Industry
Agricultural Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.3M
4.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NXTS
ARTL
Price
$4.63
$2.56
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
N/A
AVG Volume (30 Days)
19.7K
444.5K
Earning Date
05-16-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.55
$0.90
52 Week High
$6.21
$28.60

Technical Indicators

Market Signals
Indicator
NXTS
ARTL
Relative Strength Index (RSI) 61.39 33.72
Support Level $3.92 $1.62
Resistance Level $5.31 $3.67
Average True Range (ATR) 0.62 0.27
MACD -0.08 -0.14
Stochastic Oscillator 42.82 2.31

Price Performance

Historical Comparison
NXTS
ARTL

About NXTS Nexentis Technologies Inc. Common Stock

Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: